drugset / Trial / NCT04097405

Phase I Study of D-0120 to Evaluate Safety and PK/PD Study in Healthy Volunteers

NCT04097405

Phase 1 Completed 40 enrolled InventisBio Co., Ltd
RandomizedSequentialTriple-blindOther

Summary

This phase 1 study is a randomized, double-blind, placebo controlled, multiple-dose, dose-escalating study to evaluate the safety, tolerability, PK and PD of D-0120 in healthy volunteers.

Timeline

Start
2019-09-18
Primary completion
2020-03-30
Completion
2020-11-18

Drugs

EvaluationDrugModalityDoseRoute
Subject D-0120 Unknown

Indications

No indication recorded.